Homepage>Company>Media>Pharma News>2022>Timber Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis
Timber Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis